Evidence map›Paper›PMID 40371227›Full record

ArticleFrontiers in oncology2025

Epigenetic disruption of adipogenic gene enhancers in dedifferentiated liposarcomas and its therapeutic value.

Naoko Hattori, Hironori Takamatsu, Naoko Iida, Naofumi Asano, Satoshi Yamashita, Gina Miku Oba, Kozue Kimura, Akihiko Yoshida, Eisuke Kobayashi, Robert Nakayama and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Naoko Hattori *Department of Epigenomics, Institute for Advanced Life Sciences, Hoshi University, Tokyo, Japan.
Hironori Takamatsu *Division of Epigenomics, National Cancer Center Research Institute, Tokyo, Japan.
Naoko IidaDivision of Epigenomics, National Cancer Center Research Institute, Tokyo, Japan.
Naofumi AsanoDepartment of Orthopaedic Surgery, Keio University School of Medicine, Tokyo, Japan.
Satoshi YamashitaDepartment of Life Engineering, Faculty of Engineering, Maebashi Institute of Technology, Maebashi, Japan.
Gina Miku ObaLaboratory of Computational Genomics, Institute for Quantitative Biosciences, The University of Tokyo, Tokyo, Japan.
Kozue KimuraLaboratory of Integrative Metabolic Regulation, Institute for Molecular and Cellular Regulation, Gunma University, Maebashi, Japan.
Akihiko YoshidaDepartment of Diagnostic Pathology, National Cancer Center Hospital, Tokyo, Japan.
Eisuke KobayashiDepartment of Orthopaedic Surgery, Keio University School of Medicine, Tokyo, Japan.
Robert NakayamaDepartment of Orthopaedic Surgery, Keio University School of Medicine, Tokyo, Japan.
Morio MatsumotoDepartment of Orthopaedic Surgery, Keio University School of Medicine, Tokyo, Japan.
Masaya NakamuraDepartment of Orthopaedic Surgery, Keio University School of Medicine, Tokyo, Japan.
Akira KawaiDepartment of Musculoskeletal Oncology, National Cancer Center Hospital, Tokyo, Japan.
Toshikazu UshijimaDepartment of Epigenomics, Institute for Advanced Life Sciences, Hoshi University, Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Liposarcoma (LPS) is the most common soft-tissue sarcoma in adults, and well-differentiated liposarcoma (WDLPS) and dedifferentiated liposarcoma (DDLPS) are the most frequent subtypes. These LPSs are considered to develop due to disturbances in the adipogenic differentiation of mesenchymal stem cells. However, the molecular mechanisms underlying the disturbances remain unclear. Here, we aimed to identify the mechanism and explore its therapeutic advantages focusing upon their epigenetic alterations, known to be important in differentiation. First, we conducted a genome-wide DNA methylation analysis using 15 LPSs (6 WDLPSs and 9 DDLPSs) and 6 normal adipose tissues. Unsupervised hierarchical cluster analysis using DNA methylation profiles at enhancers classified the samples into the three histological types, whereas analysis using promoters did not. Principal component analysis revealed that normal adipose tissues and WDLPSs were grouped closely, whereas DDLPSs were scattered. Genomic regions hypermethylated in DDLPSs were enriched for enhancers, especially super-enhancers (13.5% of hypermethylated regions and 7.0% of the whole genome), which were located in the genes involved in adipogenesis, such as

Indexed as

adipogenic differentiationDNA demethylating agentDNA methylationepigenomesarcoma

Identifiers

PMID40371227
PMCPMC12074953

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.